viewe-Therapeutics plc

e-Therapeutics plc focused on commercialisation and making alliances

e-Therapeutics plc (LON:ETX) is targeting partners to accelerate the development of its drug discovery engine, it told investors on Tuesday.

Malcolm Young, chief executive, tells Proactive that “making alliances with much larger companies is absolutely our foreground so that’s where we need to go, that’s where our frontier is, that’s where we need to make the advances.”

He adds “commercialisation as a focus in the company has really grown in significance in this last year,” and that the firm is looking for partnerships as a way to recognise the commercial value of both late stage and early stage products.

Quick facts: e-Therapeutics plc

Price: 5.1 GBX

Market: AIM
Market Cap: £13.73 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...



e-Therapeutics continuing to convert business development into cash...

e-Therapeutics PLC's (LON:ETX) Ray Barlow says they're actively engaged in exploring all organic and non-organic opportunities that have the potential to create incremental value for its shareholders. He adds that multiple proposals for its artificial intelligence-based drug research products...

on 7/10/19

2 min read